NCT06655818View on ClinicalTrials.gov

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

February 14, 2024

Study Completion Date

February 14, 2024

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

Belantamab Mafodotin

Belantamab Mafodotin will be administered.

DRUG

Dostarlimab

Dostarlimab will be administered.

Trial Locations (3)

Unknown

GSK Investigational Site, Lille

GSK Investigational Site, Seoul

GSK Investigational Site, Ulsan

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06655818 - Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM | Biotech Hunter | Biotech Hunter